Anti-ulcer Activity using Pylorus Ligation (Shay Rat) and Ethanol Models

1. Introduction

Preclinical evaluation of potential anti-ulcer agents represents a critical phase in the development of novel therapeutics for gastroduodenal disorders. Among the various experimental paradigms, the pylorus ligation model, commonly referred to as the Shay rat model, and ethanol-induced gastric lesion models are established and widely utilized methodologies. These models serve to simulate distinct pathophysiological pathways leading to gastric mucosal injury, thereby providing a robust framework for the initial screening and mechanistic investigation of drug candidates. The enduring relevance of these models lies in their ability to generate reproducible, quantifiable data on ulcerogenesis and the protective or curative effects of pharmacological interventions.

The historical development of these models is rooted in mid-20th-century experimental physiology. The pylorus ligation technique was systematically described by Shay and colleagues in 1945 as a method to induce gastric ulcers by preventing gastric emptying, leading to the accumulation of acid and pepsin. Concurrently, the exploration of necrotizing agents like ethanol to create acute mucosal damage provided a complementary model for studying rapid cytoprotective mechanisms. Together, these approaches have formed the cornerstone of anti-ulcer drug discovery for decades, contributing significantly to the development and understanding of agents such as proton pump inhibitors, H₂-receptor antagonists, and mucosal protectants.

The importance of these models in pharmacology and medicine cannot be overstated. They bridge fundamental research on gastric mucosal defense with applied therapeutic development. By offering insights into secretory, barrier, and healing mechanisms, they guide the selection of compounds for further clinical trials. Furthermore, they remain essential educational tools for demonstrating core principles of experimental pharmacology, gastrointestinal physiology, and drug evaluation protocols to medical and pharmacy students.

Learning Objectives

• Explain the fundamental principles and procedural methodology underlying the pylorus ligation (Shay rat) and ethanol-induced gastric ulcer models.
• Analyze the distinct pathophysiological mechanisms of ulcer induction in each model and their correlation with human ulcer disease.
• Describe the standard parameters measured to quantify ulcer severity and the subsequent calculation of anti-ulcer activity indices such as ulcer index, percentage inhibition, and secretory parameters.
• Evaluate the clinical significance of data derived from these models in predicting therapeutic efficacy for acid-related and mucosal integrity disorders.
• Compare and contrast the applications of these models in the preclinical profiling of different anti-ulcer drug classes, including antisecretory, anticholinergic, cytoprotective, and antioxidant agents.

2. Fundamental Principles

The evaluation of anti-ulcer activity rests on the principle of experimentally inducing a controlled gastric injury in laboratory animals, most commonly rats, and subsequently assessing the ability of a test substance to prevent or ameliorate this injury. The choice of model dictates the predominant mechanism of injury under investigation.

Core Concepts and Definitions

Pylorus Ligation (Shay Rat Model): This is an in vivo model where surgical ligation of the pylorus is performed, preventing the exit of gastric contents. This leads to the accumulation of hydrochloric acid and pepsin, creating an environment of sustained aggressive factors against a compromised mucosal defense due to distension and ischemia, ultimately resulting in glandular ulcer formation.

Ethanol-Induced Gastric Ulcer Model: This model involves the oral administration of a necrotizing concentration of ethanol (typically >50% v/v). Ethanol rapidly disrupts the gastric mucosal barrier by denaturing surface mucus, damaging epithelial cells, and inducing vascular injury, leading to hemorrhagic lesions primarily in the glandular mucosa. It is primarily a model for assessing cytoprotective and antioxidant activities.

Ulcer Index (UI): A semi-quantitative scoring system used to grade the severity of gastric lesions based on criteria such as number, length, width, and depth of ulcers. A composite score is calculated for each animal.

Percentage Inhibition: The primary efficacy endpoint, calculated by comparing the mean ulcer index in a drug-treated group to that of a negative control (vehicle-treated) group. The formula is: Percentage Inhibition = [(UI_control – UI_treated) ÷ UI_control] × 100.

Gastric Secretory Parameters: In the Shay rat model, gastric juice is collected and analyzed for volume, pH, total acidity, and pepsin activity. These parameters are direct indicators of antisecretory drug effects.

Theoretical Foundations

The theoretical basis for these models is the imbalance between aggressive factors and defensive factors in the stomach, as encapsulated by Shay’s concept of “aggression versus defense.” Aggressive factors include gastric acid, pepsin, bile salts, Helicobacter pylori, and NSAIDs. Defensive factors comprise the mucus-bicarbonate barrier, surface epithelial cell integrity, mucosal blood flow, prostaglandins, and growth factors. The pylorus ligation model primarily augments aggressive factors (acid and pepsin), while the ethanol model primarily impairs defensive factors (barrier integrity and microcirculation). A potential anti-ulcer agent may therefore act by reducing aggression, enhancing defense, or both.

Key Terminology

• Glandular Mucosa: The region of the stomach containing acid- and pepsinogen-secreting cells; the site of ulcer formation in these models.
• Necrotizing Agent: A substance, such as concentrated ethanol, that causes cell death and tissue necrosis upon contact.
• Cytoprotection: The property of certain drugs (e.g., prostaglandin analogs) to protect gastric mucosal cells from injury by mechanisms largely independent of acid inhibition.
• Prophylactic vs. Curative Protocol: Test compounds are usually administered before ulcer induction (prophylactic) to assess preventive efficacy. Some models may involve administration after induction to study healing effects.
• Positive Control: A standard drug with known efficacy (e.g., ranitidine, omeprazole, sucralfate) included in the experimental design to validate the model’s responsiveness.

3. Detailed Explanation

A comprehensive understanding of these models requires an in-depth examination of their methodologies, mechanistic pathways, and the factors that influence their outcomes.

Methodology of the Pylorus Ligation (Shay Rat) Model

The procedure is performed under strict aseptic conditions with appropriate anesthetic oversight. Following a fasting period of 24-48 hours (with water ad libitum to ensure hydration but prevent food-derived buffering), the animal is anesthetized. A midline laparotomy is performed to expose the stomach and duodenum. The pylorus is carefully identified and ligated without occluding blood vessels. The abdominal wall and skin are then sutured closed. Post-operatively, the animal is placed in a cage with a raised wire mesh bottom to prevent coprophagy. After a standard period, typically 4 to 19 hours, the animal is euthanized, the stomach is excised, and the esophageal end is ligated to prevent content spillage.

The stomach is then opened along the greater curvature. The contents are drained into a graduated tube for analysis. The gastric mucosa is rinsed gently with saline and pinned on a cork board or wax surface for macroscopic examination. Ulcers appear as elongated, dark red or black lines in the glandular portion, parallel to the long axis of the stomach. The ulcer index is scored, and gastric juice is analyzed for volume, pH (via pH meter), total acidity (by titration with 0.01 N NaOH to pH 7.0), and pepsin activity (using an assay like the Anson method with hemoglobin substrate).

Pathophysiological Mechanisms in the Shay Model

Pyloric occlusion sets in motion a cascade of events. The continuous secretion of acid and pepsin into a closed cavity leads to progressive distension. This distension may compromise mucosal blood flow, leading to localized ischemia and reduced nutrient delivery. The accumulating acid back-diffuses into the mucosa, causing direct cellular damage and activating pepsinogen to pepsin, which then digests mucosal proteins. The combination of sustained chemical aggression and impaired mucosal defense due to vascular compromise results in focal necrosis and ulcer formation. The model is highly sensitive to antisecretory agents, making it a gold standard for evaluating acid-suppressive drugs.

Methodology of the Ethanol-Induced Gastric Ulcer Model

This model is technically simpler and does not involve surgery. Rats are fasted similarly but often for a shorter period (18-24 hours). To ensure consistent absorption and effect, animals may be pretreated with the test compound or vehicle by oral gavage. After a predetermined interval (e.g., 30-60 minutes), a necrotizing agent, most commonly absolute or 80-100% v/v ethanol, is administered orally in a standard volume (e.g., 1 mL/200 g body weight). The ethanol is given in a single bolus. One hour after ethanol administration, the animals are euthanized. The stomach is removed, opened along the greater curvature, rinsed, and examined.

Lesions induced by ethanol are typically hemorrhagic streaks or bands, predominantly in the glandular mucosa. The ulcer index is scored, often placing greater emphasis on the area of lesions. Histological examination of tissue sections can provide additional data on mucosal depth, edema, leukocyte infiltration, and bleeding.

Pathophysiological Mechanisms in the Ethanol Model

Concentrated ethanol acts as a direct necrotizing agent. Its mechanisms are multifactorial. It rapidly disrupts the hydrophobic phospholipid layer and depletes the surface mucus gel, breaking the first line of defense. Ethanol induces exfoliation of surface epithelial cells and causes deep hemorrhagic necrosis. A critical component is its effect on the microvasculature; it can cause vasoconstriction, increased vascular permeability, stasis, and microvascular rupture, leading to hemorrhagic injury. The generation of reactive oxygen species (ROS) and depletion of endogenous antioxidants like glutathione are also implicated. This model is therefore particularly relevant for evaluating agents with cytoprotective, antioxidant, or anti-inflammatory properties, such as prostaglandin analogs, flavonoids, or sulfhydryl compounds.

Quantitative Analysis and Data Interpretation

The ulcer index is calculated using a predefined scale. A common scoring system is:

• 0: Normal mucosa.
• 1: Superficial mucosal erosion (red coloration).
• 2: Deep ulcer or lesion with a length less than 2 mm.
• 3: Deep ulcer with a length between 2 and 4 mm.
• 4: Deep ulcer with a length greater than 4 mm.

For multiple ulcers, scores may be summed or an average taken per group. The percentage inhibition of ulcerogenesis is the primary efficacy measure. In the Shay model, analysis of gastric juice provides mechanistic data. A significant reduction in volume and total acidity with an increase in pH indicates antisecretory activity. Reduced pepsin activity may suggest direct inhibition or secondary reduction due to elevated pH.

Factors Affecting Model Outcomes

Several variables must be controlled to ensure reproducibility. The strain, age, sex, and weight of the rats can influence ulcer susceptibility. Fasting duration is critical; inadequate fasting leads to residual food buffering acid in the Shay model. The surgical skill in pylorus ligation, particularly avoiding vascular damage, is paramount. The dose and concentration of ethanol must be standardized. The timing of test drug administration relative to ulcer induction (pre-treatment interval) significantly affects results, especially for drugs requiring metabolic activation or with specific pharmacokinetics. Environmental stress, including handling and noise, can modulate ulcer formation via neuroendocrine pathways. The use of appropriate positive controls in every experiment is non-negotiable for validating the experimental run.

4. Clinical Significance

The translational value of data generated from these preclinical models lies in their predictive capacity for clinical efficacy and their role in elucidating mechanisms of action. While no animal model perfectly replicates human peptic ulcer disease, these models capture essential pathophysiological components.

Relevance to Drug Therapy Development

The Shay rat model has been historically instrumental in the development of acid-suppressive therapies. The correlation between a compound’s ability to reduce gastric juice volume and acidity in this model and its subsequent efficacy in treating duodenal ulcers and gastroesophageal reflux disease in humans is well-established. Drugs like cimetidine and omeprazole showed profound inhibitory effects in the Shay model during their discovery phases, correctly predicting their clinical utility. The model remains a first-line screen for any new chemical entity suspected of having antisecretory properties via H₂-receptor blockade, proton pump inhibition, or antimuscarinic activity.

The ethanol model, conversely, validated the concept of “cytoprotection” proposed by André Robert. The discovery that prostaglandins could prevent ethanol-induced lesions without affecting acid secretion led to the development of misoprostol, used clinically to prevent NSAID-induced gastric ulcers. This model is crucial for screening natural products, phytochemicals, and synthetic compounds believed to act through enhancement of mucosal defense, scavenging of free radicals, or inhibition of inflammatory mediators like TNF-α.

Practical Applications and Limitations

In practical drug discovery, these models are often used in tandem. A compound showing activity in both models may possess a dual mechanism (e.g., antisecretory and antioxidant), which could be advantageous. The models are also used for dose-ranging studies to establish effective doses (ED₅₀) and to compare potency relative to standard drugs.

However, their limitations must be acknowledged. They model acute ulcer formation, not the chronic ulceration or the role of Helicobacter pylori seen in humans. The ethanol model, in particular, represents a severe chemical injury that may not fully reflect the subtler, chronic pathophysiology of most human ulcers. Furthermore, species differences in gastric physiology, metabolism, and drug response mean that promising preclinical results require confirmation in clinical trials. These models are best viewed as essential, but not sufficient, components of a comprehensive anti-ulcer drug development program.

5. Clinical Applications and Examples

The application of these models can be illustrated through hypothetical and historical case scenarios that demonstrate their role in problem-solving and drug profiling.

Case Scenario 1: Profiling a Novel Synthetic Compound

A pharmaceutical research team synthesizes a new chemical entity (NCE-X) suspected to have anti-ulcer properties based on its structural similarity to known H₂-antagonists. To characterize its activity, a preclinical study is designed using both models.

Study Design: Rats are divided into five groups (n=6): Group I (Normal control, no ligation/ethanol), Group II (Ulcer control, vehicle), Group III (NCE-X, low dose), Group IV (NCE-X, high dose), Group V (Positive control, ranitidine). Drugs are administered orally 60 minutes before pylorus ligation or ethanol (1 mL/100% v/v).

Results Interpretation: In the Shay model, NCE-X shows a dose-dependent reduction in ulcer index, gastric volume, and total acidity, with a concomitant increase in gastric pH, comparable to ranitidine. This strongly suggests a primary antisecretory mechanism. In the ethanol model, NCE-X shows only modest ulcer inhibition at the high dose, significantly less than that seen with a cytoprotective agent like misoprostol. This profile indicates NCE-X is primarily an acid-suppressive agent, guiding the research team to focus subsequent studies on its receptor affinity, pharmacokinetics, and potential for drug interactions typical of this class, rather than on antioxidant pathways.

Case Scenario 2: Evaluating a Herbal Extract

A traditional medicinal plant extract (Plantex) is claimed to have gastroprotective effects. An investigation is undertaken to substantiate this claim and probe its mechanism.

Study Design: Similar group design is used, with Plantex at two doses and omeprazole (for Shay) and sucralfate (for ethanol) as positive controls.

Results Interpretation: In the ethanol model, Plantex demonstrates potent, dose-dependent ulcer inhibition, even exceeding sucralfate’s effect. Histology reveals preserved mucosal architecture and reduced neutrophil infiltration. However, in the Shay model, its effect on ulcer index is mild, and it causes no significant change in gastric secretion parameters. This pattern is classic for a cytoprotective agent. Further in vitro assays prompted by these findings may reveal that Plantex has high antioxidant capacity, stimulates mucosal prostaglandin E₂ synthesis, or enhances mucus secretion. This directs its potential clinical application towards conditions involving barrier disruption, such as prophylaxis against NSAID-induced gastropathy or treatment of acute gastritis, rather than as a primary therapy for acid-hypersecretory disorders.

Application to Specific Drug Classes

The differential responsiveness of these models helps categorize drug actions:

• Proton Pump Inhibitors (e.g., Omeprazole): Highly effective in the Shay model, dramatically reducing acidity and ulcer index. Minimal direct effect in the acute ethanol model unless given in a pre-dosing regimen to allow systemic effects, highlighting their systemic, mechanism-based action requiring active parietal cells.
• Prostaglandin Analogs (e.g., Misoprostol): Highly effective in the ethanol model at very low doses, demonstrating cytoprotection. They may show some activity in the Shay model by reducing acid secretion, but their hallmark is the profound protection in the absence of acid suppression.
• Sucralfate and Colloidal Bismuth: These mucosal protectants are more effective in the ethanol model, where they form a adherent barrier at the ulcer site. Their activity in the Shay model is moderate, primarily due to local buffering and adsorption of pepsin rather than profound acid reduction.
• Antioxidants and Flavonoids (e.g., Quercetin, Silymarin): Typically show strong activity in the ethanol model by countering oxidative stress. Their effects in the Shay model are variable and often secondary.

6. Summary and Key Points

The pylorus ligation and ethanol-induced gastric ulcer models are foundational tools in experimental pharmacology for the preclinical assessment of anti-ulcer agents.

Summary of Main Concepts

• The Pylorus Ligation (Shay Rat) Model induces ulcers via the accumulation of gastric acid and pepsin secondary to outlet obstruction, modeling hypersecretory states. It is the benchmark for evaluating antisecretory drugs (PPIs, H₂-blockers).
• The Ethanol-Induced Gastric Ulcer Model creates rapid necrotizing damage by disrupting the mucosal barrier and microcirculation. It is the primary model for assessing cytoprotective, antioxidant, and barrier-enhancing agents.
• The core efficacy measurement is the Ulcer Index, from which the Percentage Inhibition of ulcerogenesis is calculated: [(UI_control – UI_treated) ÷ UI_control] × 100.
• The Shay model provides additional quantitative data on gastric secretory parameters (volume, pH, total acidity, pepsin activity), offering direct insight into a drug’s mechanism.
• Used in conjunction, these models allow for a preliminary mechanistic classification of a test substance as primarily antisecretory, primarily cytoprotective, or possessing a dual action.

Clinical and Experimental Pearls

• A compound active only in the Shay model likely targets acid-pepsin secretion. Its clinical utility would be predicted for duodenal ulcers, GERD, and Zollinger-Ellison syndrome.
• A compound active only in the ethanol model likely acts on mucosal defense mechanisms. Its potential clinical niche may be in preventing NSAID ulcers, treating acute hemorrhagic gastritis, or as an adjunct therapy.
• Activity in both models suggests a multifaceted pharmacodynamic profile, which may be advantageous for broad-spectrum gastroprotection but requires careful clinical trial design to demonstrate specific benefits.
• Rigorous standardization of animal variables, fasting protocols, surgical technique (for Shay), and necrotizing agent concentration (for ethanol) is essential for reproducible and interpretable results.
• The inclusion of appropriate positive control groups in every experiment is a fundamental requirement to validate the model’s performance and provide a benchmark for the test compound’s efficacy.

These models, despite their limitations regarding chronicity and specific etiology, continue to provide invaluable, mechanistically informative data that form a critical bridge between molecular discovery and clinical application in gastroenterological pharmacology.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
5. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.